Viehbacher
Principal executive officer pay for Viehbacher, by year and company, from pay-versus-performance disclosure. Every figure links to its source on the company page.
BIOGEN INC. (BIIB) FY2022–FY2025
Lagged peersTSR -23% vs peer group 8% over FY2022–FY2025
Paid for declineCAP $27,551,849→$27,664,592 while $100 invested went $93.32→$71.87 (FY2022–FY2025)
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2022 | $30.5M | $27.6M |
| FY2023 | $4.1M | -$4.5M |
| FY2024 | $24.2M | $1.3M |
| FY2025 | $23.6M | $27.7M |
The company's "$100 invested" index ran $93.32 at FY2022 → $71.87 by FY2025 — an annualized return of -8.3%.
Track record
1 measurable tenure in the pay-versus-performance disclosure window. Best annualized TSR: -8.3%/yr at BIIB ( FY2022–FY2025). See the CEO track-record ranking for context.